Literature DB >> 32871812

Combination of 1st and 2nd Week Dosing of Glass Yttrium-90 Microspheres for Superselective Radioembolization.

Hyo-Cheol Kim1, Myungsu Lee2, Jeong-Hoon Lee3, Jin Chul Paeng4, Yoon Jun Kim3, Jin Wook Chung2.   

Abstract

BACKGROUND/AIM: The aim of this study was to address the feasibility of combination of 1st and 2nd week dosing of glass microspheres in the setting of selective radioembolization for large hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Yttrium-90 radioembolization was performed in 53 patients with single nodular hepatocellular carcinomas larger than 5 cm. A total of 32 patients underwent radioembolization with glass microspheres from a single calibration date (single-dosing group), and 21 patients were treated with a combination of 1st and 2nd week dosing of glass microspheres (combined-dosing group). In the combined-dosing group, the lobar hepatic arteries and subsidiary tumor-feeding arteries were commonly treated with 1st and 2nd week dosing of glass microspheres, respectively.
RESULTS: The combined-dosing group tended to have a lower frequency of pain requiring analgesics without statistical significance (p=0.085). The objective response rate at 3 months in single-dosing group and combined-dosing group was 46.9% (15 out of 32) and 66.7% (14 out of 21), respectively.
CONCLUSION: The combined 1st and 2nd week dosing of glass microspheres demonstrated an acceptable toxicity and tumor response when both a lobar hepatic artery and a small tumor-feeding artery need to be treated in one session. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Radioembolization; hepatocellular carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32871812      PMCID: PMC7652468          DOI: 10.21873/invivo.12100

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  14 in total

1.  Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Jon Bell; Carlo Chiesa; Kirk Fowers; Bonnie Hamilton; Joseph Herman; S Cheenu Kappadath; Thomas Leung; Lorraine Portelance; Daniel Sze; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-16       Impact factor: 9.236

Review 2.  Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions.

Authors:  Siddharth A Padia; Robert J Lewandowski; Guy E Johnson; Daniel Y Sze; Thomas J Ward; Ron C Gaba; Mark O Baerlocher; Vanessa L Gates; Ahsun Riaz; Daniel B Brown; Nasir H Siddiqi; T Gregory Walker; James E Silberzweig; Jason W Mitchell; Boris Nikolic; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2016-11-09       Impact factor: 3.464

3.  Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.

Authors:  Robert J Lewandowski; Jeet Minocha; Khairuddin Memon; Ahsun Riaz; Vanessa L Gates; Robert K Ryu; Kent T Sato; Reed Omary; Riad Salem
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-10       Impact factor: 9.236

4.  Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma.

Authors:  Derek M Biederman; Joseph J Titano; Ricki A Korff; Aaron M Fischman; Rahul S Patel; Francis S Nowakowski; Robert A Lookstein; Edward Kim
Journal:  J Vasc Interv Radiol       Date:  2017-11-21       Impact factor: 3.464

5.  Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study.

Authors:  Siddharth A Padia; Guy E Johnson; Kathryn J Horton; Christopher R Ingraham; Matthew J Kogut; Sharon Kwan; Sandeep Vaidya; Wayne L Monsky; James O Park; Renuka Bhattacharya; Daniel S Hippe; William P Harris
Journal:  J Vasc Interv Radiol       Date:  2017-03-30       Impact factor: 3.464

6.  Combination Ipsilateral Lobar and Segmental Radioembolization Using Glass Yttrium-90 Microspheres for Treatment of Multifocal Hepatic Malignancies.

Authors:  Bulent Arslan; Muhammad Talha Padela; Sreekumar Madassery; Abdulrahman Masrani; Jordan Tasse; Mark Supanich; Osman Ahmed
Journal:  J Vasc Interv Radiol       Date:  2018-08       Impact factor: 3.464

7.  Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization.

Authors:  Hyo-Cheol Kim; Jin Wook Chung; Whal Lee; Hwan Jun Jae; Jae Hyung Park
Journal:  Radiographics       Date:  2005-10       Impact factor: 5.333

8.  Yttrium-90 Radioembolization of the Right Inferior Phrenic Artery in 20 Patients with Hepatocellular Carcinoma.

Authors:  Hyo-Cheol Kim; Yoon Jun Kim; Jin Chul Paeng; Jin Wook Chung
Journal:  J Vasc Interv Radiol       Date:  2018-04       Impact factor: 3.464

9.  Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients.

Authors:  Jin Wook Chung; Hyo-Cheol Kim; Jung-Hwan Yoon; Hyo-Suk Lee; Hwan Jun Jae; Whal Lee; Jae Hyung Park
Journal:  Korean J Radiol       Date:  2006 Oct-Dec       Impact factor: 3.500

Review 10.  Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know.

Authors:  Ijin Joo; Hyo-Cheol Kim; Gyoung Min Kim; Jin Chul Paeng
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.